# US 2016/0258951 A1 · Methods of monitoring immune responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0258951 A1
- Document ID: US20160258951A1
- Status: Published application
- Kind: A1
- Application number: 15/032,820
- Filed: 2014-10-28
- Published: 2016-09-08
- Earliest claimed: 2013-10-28
- Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Inventors: Sathibalan Ponniah; George E. Peoples; Catherine Storrer
- Web page: https://patentgrep.com/patent/US20160258951A1

## CPC

- G01N 33/56966: {Animal cells}
- G01N 33/505: {involving T-cells}
- G01N 33/57515: of the breast
- G01N 33/6878: {in epitope analysis}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The human HLA-A2:1g dimer molecule is a recombinant protein comprising a mouse IgG antibody fused with two human MHC Class I HLA-A2 molecules. Any peptide (usually 8-10 amino acids in length) can be loaded into the peptide-binding groove of the two HLA molecules, for example, by incubating a mixture of the dimer and peptide solution overnight. The resulting N peptide-specific HLA-A2:1g dimer mixture can then be added to PBMCs from peripheral blood samples in order to detect CD8 T lymphocytes which express T cell receptors that are capable of specifically interacting with and binding to the peptide HLA-A2:1g dimer molecules. The presence of such specific binding activity and interactions can then be detected by additional staining with fluorescence-conjugated antibodies.

## Claims

### Claim 1

A method of monitoring an immune response to a test peptide, the method comprising:
(a) incubating peripheral blood mononuclear cells (PBMCs) obtained from a patient with a fusion protein comprising a mouse immunoglobulin fused to two human MEW class I HLA molecules, wherein the test peptide has been loaded into the peptide binding groove of the two human MEW class I HLA molecules;
(b) quantitating the cytotoxic CD8 T cells specific for the test peptide; and
(c) normalizing the result obtained in step (b) by subtracting a background value obtained by quantitating the cytotoxic CD8 T cells specific for a negative control peptide, wherein the negative control peptide is the E37 peptide having the amino acid sequence RIAWARTEL (SEQ ID NO:4).

### Claim 2

A method of monitoring an immune response to a test peptide, the method comprising:
(a) incubating peripheral blood mononuclear cells (PBMCs) obtained from a patient with a fusion protein comprising a mouse immunoglobulin fused to two human MEW class I HLA molecules, wherein the test peptide has been loaded into the peptide binding groove of the two human MEW class I HLA molecules;
(b) incubating PBMCs obtained from the patient with the fusion protein, wherein a negative control peptide has been loaded into the peptide binding groove of the two human MHC class I HLA molecules, and wherein the negative control peptide is the E37 peptide having the amino acid sequence RIAWARTEL (SEQ ID NO:4);
(c) quantitating the cytotoxic CD8 T cells specific for the test peptide;
(d) quantitating the cytotoxic CD8 T cells specific for the negative control peptide to obtain a background value;
(e) normalizing the result obtained in step (c) by subtracting the background value obtained in step (d).

### Claim 3 (depends on 1)

The method of claim 1, wherein the background value is about 0.3%.

### Claim 4 (depends on 1)

The method of claim 1, wherein the test peptide is a class I restricted Her2/neu derived peptide.

### Claim 5 (depends on 4)

The method of claim 4, wherein the test peptide is E75, GP2, GP2′, or Her577.

### Claim 6 (depends on 4)

The method of claim 4, wherein the test peptide is E75.

### Claim 7 (depends on 1)

The method of claim 1, wherein the fusion protein comprises a mouse IgG fused to two human MHC class I HLA-A2 molecules.

### Claim 8 (depends on 1)

The method of claim 1, wherein quantitating the cytotoxic T cells specific for the test peptide is achieved using immunofluorescent staining or fluorescent activated cell sorting (FACS).

### Claim 9 (depends on 1)

The method of claim 1, further comprising a step before (a) of loading the test peptide into the peptide binding groove of the two human MHC class I HLA molecules of the fusion protein.

### Claim 10 (depends on 9)

The method of claim 9, wherein the loading step comprises incubating the test peptide with the fusion protein overnight at 37° C.

### Claim 11 (depends on 1)

The method of claim 1, wherein quantitating the cytotoxic T cells specific for the test peptide is expressed as a dimer index.

### Claim 12 (depends on 1)

The method of claim 1, wherein the method is used to assess the clinical response of a HER2/neu derived peptide vaccine in a breast cancer patient, wherein the breast cancer patient is disease free following standard therapy.

### Claim 13 (depends on 12)

The method of claim 12, wherein the HER2/neu derived peptide vaccine comprises E75 and GM-CSF or GP2 and GM-CSF.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cytotoxic CD8 T cells specific for the test peptide are quantified at baseline, after a primary vaccination, and at 6 months post primary vaccination.

### Claim 15 (depends on 1)

The method of claim 1, wherein a more robust cytotoxic CD8 T cell response to the test peptide at 6 months post primary vaccination indicates that the patient is less likely to experience breast cancer recurrence or more likely to have a longer disease free survival.

### Claim 16 (depends on 1)

The method of claim 1, wherein a low cytotoxic CD8 T cell response to the test peptide at baseline indicates that the patient is less likely to experience breast cancer recurrence or more likely to have a longer disease free survival.

### Claim 17 (depends on 16)

The method of claim 16, wherein the patient has low to intermediate HER2 expression (IHC 1 or 2+ or FISH<2.2).

### Claim 18

A kit comprising a fusion protein comprising a mouse immunoglobulin fused to two human MHC class I HLA molecules and a negative control peptide, wherein the negative control peptide is an E37 peptide having the amino acid sequence RIAWARTEL (SEQ ID NO:4).

### Claim 19 (depends on 18)

The kit of claim 18, further comprising a positive control peptide.

### Claim 20 (depends on 18)

The kit of claim 18, further comprising a test peptide, wherein the test peptide is a class I restricted Her2/neu derived peptide.

### Claim 21 (depends on 20)

The kit of claim 20, wherein the test peptide is E75, GP2, GP2′, or Her577.

### Claim 22 (depends on 18)

The kit of claim 18, wherein the fusion protein comprises a mouse IgG fused to two human MHC class I HLA-A2 molecules.

### Claim 23 (depends on 18)

The kit of claim 18, further comprising a labeled antibody that binds to the immunoglobulin of the fusion protein.

### Claim 24 (depends on 18)

The kit of claim 18, wherein the E37 peptide is loaded into the peptide binding groove of the two human MHC class I HLA molecules of the fusion protein.

### Claim 25 (depends on 19)

The kit of claim 19, wherein the test peptide is loaded into the peptide binding groove of the two human MHC class I HLA molecules of the fusion protein.

### Claim 26 (depends on 18)

The kit of claim 18, further comprising a buffer for diluting one or more of the negative control peptide, positive control peptide, or test peptide.
